OR WAIT null SECS
Roquette has launched excipients PEARLITOL CR-H and PEARLITOL 200 GT.
Roquette, a global leader in plant-based ingredients and provider of pharmaceutical and nutraceutical excipients, announced on Oct. 31, 2022 the launch of two next-generation mannitol products for direct compression. The excipients are called PEARLITOL CR-H and PEARLITOL 200 GT and are designed to overcome unique drug formulation challenges and help manufacturers optimize direct compression processes, as well as expand into novel application areas.
PEARLITOL CR-H is a patented blend of mannitol and hydroxypropyl methylcellulose (HPMC) that allows for the sustained release of APIs in direct compression formulations. This may create new opportunities to enter the controlled-release drug delivery space, which typically requires wet granulation processes. The co-processed mannitol and HPMC brings other functional properties, such as flowability, to help optimize tablet processibility.
PEARLITOL 200 GT is a granulated mannitol excipient designed to enhance tableting performance. It addresses the capping and sticking issues that are common in other excipient solutions. It also facilitates the development of harder, smaller tablets that can be used in novel pharmaceutical applications, such as fast-dissolving medications.
Visitors are invited to join Roquette’s experts at CPHI in Frankfurt, Germany, on Nov. 1–3, 2022 at stand 80C90 to gain insights about their latest innovations.